Therapeutic Outcomes in <scp>VEXAS</scp> Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents
Saubia Fathima(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), David Dingli, A. Saliba(Mayo Clinic), Matthew J. Koster(Mayo Clinic in Arizona), M. Hefazi(Mayo Clinic), Hemant S. Murthy(University of Florida), M. R. Litzow(Mayo Clinic), Horatiu Olteanu(Mayo Clinic in Arizona), Urshila Durani(Mayo Clinic), Saurabh Chhabra(Medical College of Wisconsin), Ronald S. Go(Mayo Clinic), James M. Foran(Memorial Sloan Kettering Cancer Center), Aasiya Matin(Mayo Clinic in Arizona), Joseph P. McGuirk(University of Kansas Medical Center), Amelia Langston(CancerCare Manitoba), David B. Beck(Center for Human Genetics), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Talha Badar(Mayo Clinic in Florida), Kebede H. Begna(Mayo Clinic), William J. Hogan(Mayo Clinic), Gary Ho(New York University), Kimberly J. Langer(Mayo Clinic), Maria Sirenko(Center for Human Genetics), Nathan Punwani(Mayo Clinic in Florida), Jesus Gonzalez-Lugo(The University of Kansas Cancer Center), Aref Al-Kali(Mayo Clinic), Megan Sullivan(Mayo Clinic in Arizona), Kaaren K. Reichard(Mayo Clinic), Mary Riwes(University of Michigan), Ali Alsugair(Mayo Clinic), Christy Finke(Mayo Clinic), Tariq Kewan(Mayo Clinic), Susan M. Geyer(Mayo Clinic in Florida), Jeanne Palmer(Mayo Clinic in Florida), Margaret Mei‐Kay Wong(Center for Human Genetics), Maher Abdul‐Hay(NYU Langone Health), Elizabeth F. Krakow(Fred Hutch Cancer Center), Mithun V. Shah(Mayo Clinic), Jun Choi(NYU Langone Health), Taxiarchis Kourelis(Mayo Clinic), Jade Kutzke(Mayo Clinic), Gabriel Bartoo(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), Kristen McCullough(Mayo Clinic), Naseema Gangat(Mayo Clinic in Arizona), Kenneth J. Warrington(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782